Ceres Nanosciences, Inc.

Ceres Nanosciences, Inc. (Ceres) is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology. The Nanotrap® was developed to better capture low-abundance protein biomarkers and protect them from degradation. The Nanotrap® collection process, coupled with existing clinical diagnostic platforms, improves the sensitivity and accuracy of a wide array of critical diagnostic processes. The company currently sells R&D kits containing the Nanotrap® technology for use in a broad range of research applications. Ceres' product pipeline includes advanced sample collection technologies and diagnostic tests. Ceres' lead diagnostic test in development is a direct antigen test for the diagnosis of Lyme disease. It is also developing advanced sample preservation tools for the US Department of Defense.